Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

Hana M. El Sahly,Lindsey R. Baden,Brandon Essink,Susanne Doblecki Lewis,Judith M. Martin,Evan J. Anderson,Thomas B. Campbell,Jesse Clark,Lisa A. Jackson,Carl J. Fichtenbaum,Marcus J. Zervos,Bruce Rankin,Frank Eder,Gregory Feldman,Christina Kennelly,Laurie Han-Conrad,Michael Levin,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,Laura Polakowski,John R. Mascola,Julie E. Ledgerwood,Barney S. Graham,Allison August,Heather Clouting,Weiping Deng,Shu Han,Brett Leav,Deb Manzo,Rolando Pajon,Florian Schödel,Joanne E. Tomassini,Honghong Zhou,Jacqueline M. Miller

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

2021

Abstract Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-...

Keywords:

severe acute respiratory syndrome coronavirus 2
Clinical trial
Virology
2019 20 coronavirus outbreak
Interim analysis
Coronavirus disease 2019
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations